Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neuroectodermal Tumors, Primitive × Capecitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 158 Colorectal Neoplasms 120 Rectal Neoplasms 77 Stomach Neoplasms 76 Pancreatic Neoplasms 61 Neoplasm Metastasis 51 Neoplasms 40 Colonic Neoplasms 33 Esophageal Neoplasms 26 Gallbladder Neoplasms 17 Bile Duct Neoplasms 16 Biliary Tract Neoplasms 15 Carcinoma, Hepatocellular 14 Triple Negative Breast Neoplasms 13 Cholangiocarcinoma 11 Unspecified Adult Solid Tumor, Protocol Specific 10 Adenocarcinoma 10 Adenocarcinoma Of Esophagus 9 Parkinson Disease 4, Autosomal Dominant Lewy Body 8 Liver Neoplasms 8 Carcinoma, Renal Cell 8 Breast Neoplasms, Male 8 Squamous Cell Carcinoma of Head and Neck 7 Carcinoma, Non-Small-Cell Lung 7 Ovarian Neoplasms 6 Head and Neck Neoplasms 6 Gastrointestinal Neoplasms 6 Brain Neoplasms 6 Uterine Cervical Neoplasms 5 Solid Tumor 5

Interventions

Temozolomide 6 antineoplaston AS 2-1 3 antineoplaston A10 3 Radiotherapy 3 Filgrastim 3 Paclitaxel 2 Irinotecan 2 Donepezil 2 Cyclophosphamide 2 Cisplatin 2 Carmustine 2 Bevacizumab 2 veliparib 1 trametinib 1 temsirolimus 1 spartalizumab 1 sonidegib 1 sargramostim 1 ribociclib 1 plerixafor 1 fosbretabulin 1 entinostat 1 dactolisib 1 cixutumumab 1 carboxyamido-triazole 1 azurin (50-77) 1 aldesleukin 1 adavosertib 1 Vincristine 1 Thalidomide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02358356 2022-07-05

CONTROL NETS

Australasian Gastro-Intestinal Trials Group

Phase 2 Completed

Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡